National HealthCare stock (US6359061031): valuation in focus after recent price move

National HealthCare shares remain in the spotlight on the New York Stock Exchange as investors reassess valuation metrics following a recent price move and an updated third-party fair value assessment, putting the U.S. long-term care operator’s fundamentals back into focus.

National HealthCare shares on the New York Stock Exchange are drawing renewed attention from U.S. investors after a notable price move toward the upper end of their recent trading range, prompting a fresh look at valuation metrics and fair value estimates for the long-term care operator, according to a GuruFocus analysis dated 05/28/2026.

The GuruFocus report states that National Healthcare Corp. (ticker NHC) closed at USD 184.84 on 05/28/2026, which the service compares with its proprietary GF Value estimate of USD 126.71 for the stock on the same date, implying the shares were trading roughly 45.9% above that intrinsic value gauge. Based on this framework, the article characterizes the stock as significantly overvalued relative to its modeled fair value at that point in time.

Using that 05/28/2026 closing level as a reference, National HealthCare’s market capitalization and valuation multiples are back on the radar for U.S. investors who follow New York Stock Exchange listings and health-care services names, particularly as the stock has spent recent months near the higher end of its 52-week range. While the GuruFocus piece emphasizes that its GF Score of 72 suggests a generally good company quality profile, it simultaneously flags the valuation premium as a risk point for investors focused on margin of safety concepts.

The stock’s latest pricing context follows a period in which National HealthCare continued to operate within the U.S. post-acute and long-term care market, with its financial performance and balance sheet strength underpinning the GF Score inputs cited in the 05/28/2026 assessment. The GF Score framework typically incorporates profitability, growth, financial strength and other quantitative factors, and a score around the low-70s generally signals a solid, though not exceptional, overall profile in that methodology.

Trading in National HealthCare remains active on the New York Stock Exchange under the ticker NHC in U.S. dollars, keeping the United States at the center of price discovery and corporate news flow for the company’s equity. For investors in Europe, the stock may also be available on secondary trading venues such as Tradegate in Germany in euros, though core liquidity and regulatory oversight remain anchored in the United States via NYSE listing rules and Securities and Exchange Commission reporting standards.

The 05/28/2026 GuruFocus article does not report a specific one-day company-specific news catalyst for the pricing and valuation discussion, instead treating the move and current quote as a reference point for its fair value work and its GF Score commentary. Nevertheless, the combination of a full valuation relative to its GF Value line and a still-supportive overall quality score has sparked a new round of debate among U.S. retail investors who follow NYSE health-care service stocks and compare their metrics across the sector.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: NHC
• Sector/industry: Health care services / long-term care
• Headquarters/country: Murfreesboro, United States
• Core markets: Skilled nursing, assisted living and other long-term care services in the United States
• Key revenue drivers: Occupancy and reimbursement levels at skilled nursing facilities, rehabilitation services volumes, and long-term care patient mix across its operated and managed centers
• Home exchange/listing venue: New York Stock Exchange (NHC)
• Trading currency: USD

The GuruFocus analysis notes that at a share price of USD 184.84 on 05/28/2026, National HealthCare’s GF Score was calculated at 72 out of 100, with the score supported by profitability and financial strength metrics, while valuation was identified as a weaker component due to the premium versus the modeled GF Value line.

According to the same 05/28/2026 report, the GF Value of USD 126.71 was derived from historical trading multiples, past returns and growth, and future business performance estimates for National HealthCare, leading the service to place the stock in a category it labels as significantly overvalued at the prevailing market quote on that date.

Investors in the United States who follow fundamental metrics often juxtapose such third-party fair value models with more traditional ratios such as price-to-earnings, price-to-book and enterprise value to EBITDA, particularly for health-care services providers whose earnings and cash flows are sensitive to reimbursement policies and occupancy trends.

National HealthCare: core business model

National HealthCare focuses on operating and managing a network of skilled nursing, assisted living and related health-care facilities in the United States, generating most of its revenue from patient services reimbursed by Medicare, Medicaid, private insurers and self-pay residents.

Valuation metrics and multiples for National HealthCare

With Friday’s module centered on valuation, the GF Value and GF Score reported on 05/28/2026 give one lens on how National HealthCare’s current share price lines up against a rules-based estimate of intrinsic value in the U.S. health-care services space. The GuruFocus article highlights that the market price of USD 184.84 on that date sat about 45.9% above its calculated GF Value of USD 126.71, leading the service to categorize the equity as significantly overvalued in its framework, even as it credits the company with a GF Score of 72 that points to solid underlying fundamentals.

For U.S. investors on the New York Stock Exchange, this combination of a supportive quality score and a stretched valuation indication underscores the importance of scrutinizing earnings power, cash flow durability and balance sheet resilience when assessing long-term return potential in health-care operators such as National HealthCare. While sell-side banks in the United States did not publish a widely cited new research note on 05/28/2026 itself, the presence of a premium to one fair value estimate has kept attention on how the company’s future results, capital allocation and any changes in reimbursement policy might influence valuation metrics over time.

Conclusion

The latest trading level for National HealthCare on the New York Stock Exchange, combined with the 05/28/2026 GF Value analysis, has sharpened the focus on how fully the U.S. market is currently pricing the company’s long-term care operating profile. With a GF Score of 72 indicating a fundamentally solid business but a quoted price roughly 45.9% above one fair value estimate, valuation considerations are likely to remain central to investor discussions until upcoming financial reports provide fresh data points on earnings, cash flows and capital deployment.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.